Nephrologists and rheumatologists are approaching the new products from very different perspectives EXTON, Pa. , June 17, 2022 /PRNewswire/ — With the approvals of GlaxoSmithKline’s Benlysta in lupus nephritis (LN) at the end of 2020 and Aurinia’s Lupkynis at the beginning of 2021,…
News Ticker
- [ July 1, 2022 ] Territory Manager, Atlanta, GA- Biologics – Sun Pharmaceutical Industries, Inc (USA) – Princeton, NJ Jobs
- [ July 1, 2022 ] #BIO22: Managing a biotech in turbulent times. ‘There’s a perfect shitshow out there’ News
- [ July 1, 2022 ] Lab Notes: Verrica continues push for skin disorder drug, raising $25M; Windtree weighing options News
- [ July 1, 2022 ] Lab Equipment Commissioning & Qualification Engineer/ Metrology Engineer – Rangam Consultants Inc. – Township of Warren, NJ Jobs
- [ July 1, 2022 ] FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir News
Copyright © 2022 Biotech Networks, LLC
Be the first to comment